Date: 2015-05-12
Type of information: Commercialisation agreement
Compound: Esmocard® and Esmocard Lyo® (esmolol hydrochloride)
Company: AOP Orphan Pharmaceuticals (Austria) Cardiome Pharma (Canada)
Therapeutic area: Cardiovascular diseases
Type agreement: commercialisation
Action mechanism: Beta-blocker
Disease: supraventricular tachycardia (except for pre-excitation syndromes), rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable, tachycardia and hypertension occurring in the perioperative phase and non-compensatory sinus tachycardia where, in the physician\'s judgement the rapid heart rate requires specific intervention
Details: * On May 12, 2015, Cardiome Pharma announced that the company has entered a commercialization agreement with AOP Orphan Pharma to sell AOP’s cardiovascular products, Esmocard® and Esmocard Lyo® (esmolol hydrochloride) in Italy, France, Spain and Belgium. Esmocard® is available in two presentations including a 10mg/ml 10ml solution for injection (branded as Esmocard®) and a 2500mg powder for concentrate for solution for infusion (branded as Esmocard® Lyo).
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
